Press Releases April 21, 2026 04:05 PM

American Coastal Insurance Corporation Schedules First Quarter Financial Results and Conference Call

American Coastal Insurance Corporation announces Q1 2026 earnings release date and conference call details

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
ACIC

American Coastal Insurance Corporation, a Florida-based insurance holding company specializing in insuring condominium and homeowner association properties, plans to release its Q1 2026 financial results on May 5, 2026. The company will hold a conference call immediately after, providing remarks and a Q&A session to discuss the quarter's performance.

American Coastal Insurance Corporation  Schedules First Quarter Financial Results and Conference Call
ACIC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 financial results to be released on May 5, 2026, after market close.
  • Conference call scheduled for May 5, 2026, at 5:00 p.m. ET, including live remarks and Q&A.
  • Company specializes in insuring Florida condominium and homeowner association properties, with strong financial stability ratings from Demotech and Kroll.

ST. PETERSBURG, Fla., April 21, 2026 (GLOBE NEWSWIRE) -- American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that it expects to release its financial results for the first quarter ended March 31, 2026, on Tuesday, May 5, 2026, after the close of the market. Its quarterly conference call will be held immediately thereafter, on Tuesday, May 5, 2026, at 5:00 p.m. ET.

The conference call will include live remarks followed by a question and answer (Q&A) session. Interested parties are invited to participate in the conference call and should dial-in ten (10) minutes before the conference call is scheduled to begin.

First Quarter 2026 Conference Call Details:
Tuesday, May 5, 2026 – 5:00 p.m. ET

Participant Dial-In Numbers:

United States:  877-445-9755
International:    201-493-6744

To listen to the conference call via webcast, please visit the Company's website and click on the webcast link at the top of the page or click here. The webcast will be archived and accessible for approximately 30 days following the call.

About American Coastal Insurance Corporation:
American Coastal Insurance Corporation (amcoastal.com) is the holding company of the insurance carrier, American Coastal Insurance Company, which was founded in 2007 for the purpose of insuring Condominium and Homeowner Association properties, and apartments in the state of Florida. American Coastal Insurance Company has an exclusive partnership for distribution of Condominium Association properties in the state of Florida with AmRisc Group (amriscgroup.com), one of the largest Managing General Agents in the country specializing in hurricane-exposed properties. American Coastal Insurance Company has earned a Financial Stability Rating of “A”, Exceptional’ from Demotech, and maintains an “A-” insurance financial strength rating with a Positive outlook by Kroll. ACIC maintains a ‘BBB-’ issuer rating with a Positive outlook by Kroll.

Contact Information:                
Alexander Baty                
Vice President, Finance & Investor Relations, American Coastal Insurance Corporation
[email protected]
(727) 425-8076        

Jeremy Hellman
Investor Relations, Vice President, The Equity Group
[email protected]
(212) 836-9626


Risks

  • Results may be impacted by exposure to hurricane-related claims, given focus on hurricane-exposed properties in Florida, which introduces weather-related risk to financial outcomes.
  • Insurance sector sensitivities to catastrophe losses and regulatory changes could affect quarterly performance.
  • Market reaction depends on comparison of released results to analysts' expectations and industry conditions, which remain uncertain prior to earnings announcement.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026